Website Changes
04/17/2013
The impact of improved treatment strategies on overall survival in glioblastoma patients.
04/12/2013
Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience.
04/12/2013
J Neurooncol. 2013 Apr 6. [Epub ahead of print]
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S.
Clinica di Oncologia Medica, AOU "Ospedali Riuniti", Università Politecnica delle Marche, via Tronto 10/A, 60100, Ancona, Italy, mattymo@alice.it.
Abstract
Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients` progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile.
PMID: 23564276 [PubMed - as supplied by publisher]
04/12/2013
Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma.
04/12/2013
UCLA 13th Annual Brain Tumor Conference - For patients and families
04/12/2013
Ninth Surviving Brain Tumors Awareness Event—Cleveland
04/10/2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
04/10/2013
Radiation therapy new cancer cure
04/08/2013
Feds to cut Medicare payments for cancer-fighting Gamma Knife, thanks to Congress
03/31/2013
National Walk To End Brain Tumors - New Locations!
03/29/2013
Cancer Drug That Shrinks All Tumors Set To Begin Human Clinical Trials
03/27/2013
Musella Foundation Copay assistance program is now closed
03/27/2013
Device tested to treat aggressive brain tumors
03/26/2013
IFRT offers viable alternative to WBRT
03/24/2013
NY Yankees Fundraiser June 21!
03/24/2013
Diazepam (Valium)( Inhibits Proliferation of Human Glioblastoma Cells Through Triggering a G0/G1 Cell Cycle Arrest.
03/24/2013
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.
03/24/2013
Treatment outcome and prognostic factors of adult glioblastoma multiforme.
03/20/2013
New Trial: Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
03/13/2013
“Hospice and Palliative Care“
a free seminar for people affected by all types of brain tumors…
03/13/2013
IBTA E News March 2013
03/13/2013
Body fat may help destroy brain cancer cells
03/08/2013
Bevacizumab (Avastin) treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.
03/02/2013
Dasatinib thwarts brain cancer metastasis after bevacizumab use
02/25/2013
Merck KGaA brain tumor drug fails clinical trial
which delivers brain tumor news and additions
to the website via RSS.